HCW Biologics is trading 5.57% up now at $3.60 in pre-market trading, as renewed attention to a July 29 private placement involving its CEO, board chairman, and senior business-development executive appears to be driving the move.
- The financing raised approximately $1.6 million at about $2.585 per unit.
- The CEO separately disclosed purchasing shares at $2.59.